Immunis Initiates Patient Enrollment for Muscle Atrophy Phase I/IIa Clinical Trial

Immunis, Inc. initiated patient enrollment for their Phase I/IIa clinical trial to assess Immunis’ immunomodulatory secretome product, IMM01-STEM, in patients with muscle atrophy.